TY - JOUR
T1 - Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus?
AU - Olsen, Nancy
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/8
Y1 - 2019/8
N2 - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, and standard therapy algorithms include the use of agents with generalized immunosuppressive effects. The outcomes for SLE patients have been markedly improved by this approach. However, the concept that involved organs might be targeted for treatment in an individual patient has potential to provide further benefits, offering enhanced efficacy and fewer off-target effects. This review considers how two of the most commonly involved organ systems in SLE, skin and kidney, might be targets for new therapeutic approaches based on knowledge of underlying mechanisms of disease.
AB - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, and standard therapy algorithms include the use of agents with generalized immunosuppressive effects. The outcomes for SLE patients have been markedly improved by this approach. However, the concept that involved organs might be targeted for treatment in an individual patient has potential to provide further benefits, offering enhanced efficacy and fewer off-target effects. This review considers how two of the most commonly involved organ systems in SLE, skin and kidney, might be targets for new therapeutic approaches based on knowledge of underlying mechanisms of disease.
UR - http://www.scopus.com/inward/record.url?scp=85066070176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066070176&partnerID=8YFLogxK
U2 - 10.1016/j.rdc.2019.04.004
DO - 10.1016/j.rdc.2019.04.004
M3 - Review article
C2 - 31277750
AN - SCOPUS:85066070176
SN - 0889-857X
VL - 45
SP - 369
EP - 377
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
IS - 3
ER -